Beckel Jonathan M, Daugherty Stephanie L, Tyagi Pradeep, Wolf-Johnston Amanda S, Birder Lori A, Mitchell Claire H, de Groat William C
Department of Anaesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA; Department of Anatomy and Cell Biology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, 19104, USA.
J Physiol. 2015 Apr 15;593(8):1857-71. doi: 10.1113/jphysiol.2014.283119. Epub 2015 Feb 11.
ATP is released through pannexin channels into the lumen of the rat urinary bladder in response to distension or stimulation with bacterial endotoxins. Luminal ATP plays a physiological role in the control of micturition because intravesical perfusion of apyrase or the ecto-ATPase inhibitor ARL67156 altered reflex bladder activity in the anaesthetized rat. The release of ATP from the apical and basolateral surfaces of the urothelium appears to be mediated by separate mechanisms because intravesical administration of the pannexin channel antagonist Brilliant Blue FCF increased bladder capacity, whereas i.v. administration did not. Intravesical instillation of small interfering RNA-containing liposomes decreased pannexin 1 expression in the rat urothelium in vivo and increased bladder capacity. These data indicate a role for pannexin-mediated luminal ATP release in both the physiological and pathophysiological control of micturition and suggest that urothelial pannexin may be a viable target for the treatment of overactive bladder disorders.
ATP is released from the bladder epithelium, also termed the urothelium, in response to mechanical or chemical stimuli. Although numerous studies have described the contribution of this release to the development of various bladder disorders, little information exists regarding the mechanisms of release. In the present study, we examined the role of pannexin channels in mechanically-induced ATP release from the urothelium. PCR confirmed the presence of pannexin 1 and 2 mRNA in rat urothelial tissue, whereas immunofluorescence experiments localized pannexin 1 to all three layers of the urothelium. During continuous bladder cystometry in anaesthetized rats, inhibition of pannexin 1 channels using carbenoxolone (CBX) or Brilliant Blue FCF (BB-FCF) (1-100 μm, intravesically), or by using intravesical small interfering RNA, increased the interval between voiding contractions. Intravenous administration of BB-FCF (1-100 μg kg(-1) ) did not alter bladder activity. CBX or BB-FCF (100 μm intravesically) also decreased basal ATP concentrations in the perfusate from non-distended bladders and inhibited increases in ATP concentrations in response to bladder distension (15 and 30 cmH2 O pressure). Intravesical perfusion of the ATP diphosphohydrolase apyrase (2 U ml(-1) ), or the ATPase inhibitor ARL67156 (10 μm) increased or decreased reflex bladder activity, respectively. Intravesical instillation of bacterial lipopolysaccharides (LPS) (Escherichia coli 055:B5, 100 μg ml(-1) ) increased ATP concentrations in the bladder perfusate, and also increased voiding frequency; these effects were suppressed by BB-FCF. These data indicate that pannexin channels contribute to distension- or LPS-evoked ATP release into the lumen of the bladder and that luminal release can modulate voiding function.
响应扩张或细菌内毒素刺激,三磷酸腺苷(ATP)通过泛连接蛋白通道释放到大鼠膀胱腔内。腔内ATP在排尿控制中发挥生理作用,因为膀胱内灌注腺苷三磷酸双磷酸酶或胞外ATP酶抑制剂ARL67156会改变麻醉大鼠的膀胱反射活动。来自尿路上皮细胞顶端和基底外侧表面的ATP释放似乎由不同机制介导,因为膀胱内给予泛连接蛋白通道拮抗剂亮蓝FCF可增加膀胱容量,而静脉注射则无此作用。膀胱内滴注含小干扰RNA的脂质体可在体内降低大鼠尿路上皮细胞中泛连接蛋白1的表达并增加膀胱容量。这些数据表明泛连接蛋白介导的腔内ATP释放在排尿的生理和病理生理控制中均起作用,并提示尿路上皮泛连接蛋白可能是治疗膀胱过度活动症的可行靶点。
响应机械或化学刺激,ATP从膀胱上皮(也称为尿路上皮)释放。尽管众多研究描述了这种释放对各种膀胱疾病发展的作用,但关于释放机制的信息却很少。在本研究中,我们研究了泛连接蛋白通道在机械诱导的尿路上皮ATP释放中的作用。聚合酶链反应(PCR)证实大鼠尿路上皮组织中存在泛连接蛋白1和2的信使核糖核酸(mRNA),而免疫荧光实验将泛连接蛋白1定位到尿路上皮的所有三层。在麻醉大鼠的连续膀胱测压过程中,使用甘珀酸(CBX)或亮蓝FCF(BB - FCF)(1 - 100μm,膀胱内)或通过膀胱内小干扰RNA抑制泛连接蛋白1通道,增加了排尿收缩之间的间隔。静脉注射BB - FCF(1 - 100μg kg⁻¹)未改变膀胱活动。CBX或BB - FCF(膀胱内100μm)也降低了未扩张膀胱灌流液中的基础ATP浓度,并抑制了对膀胱扩张(15和30 cmH₂O压力)的ATP浓度增加。膀胱内灌注ATP二磷酸水解酶腺苷三磷酸双磷酸酶(2 U ml⁻¹)或ATP酶抑制剂ARL67156(10μm)分别增加或降低膀胱反射活动。膀胱内滴注细菌脂多糖(LPS)(大肠杆菌055:B5,100μg ml⁻¹)增加了膀胱灌流液中的ATP浓度,也增加了排尿频率;这些作用被BB - FCF抑制。这些数据表明泛连接蛋白通道有助于扩张或LPS诱发的ATP释放到膀胱腔内,且腔内释放可调节排尿功能。